TRINITY BIOTECH PLC
Business
TRINITY BIOTECH PLC develops, acquires, manufactures and markets medical diagnostic products for clinical laboratory and point-of-care use. Its product portfolio includes rapid HIV and infectious disease tests, ELISA kits, haemoglobin A1c and haemoglobin variant analyzers, autoimmune assays, clinical chemistry reagents, blood bank screening assays and biosensor continuous glucose monitoring (CGM) technology. The business operates through specialized subsidiaries and R&D groups focused on haemoglobins, infectious diseases, autoimmune and biosensor/CGM development. Products are sold via direct sales in key markets (notably the U.S. and Brazil), plus distributors and strategic partners into approximately 100 countries.
Summary from filing dated 2025-05-16
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | — |
| Total assets | $105.17M |
| Total liabilities | $177.15M |
| Stockholders' equity | — |
| Operating cash flow | — |